Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MMP8 | P22894 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.42 |
| ▸ | PAM | P19021 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20109359 | 0.89 | KMT2A (0.47) | ALDH1A1MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL20109336 | 0.87 | MEN1 (0.49) | ALDH1A1MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL20109356 | 0.86 | MAPT (0.47) | ALDH1A1MAPTSMN1; SMN2L3MBTL1 | |
| SCHEMBL20109358 | 0.86 | KMT2A (0.48) | ALDH1A1MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL28547028 | 0.85 | MEN1 (0.49) | ALDH1A1MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL20109355 | 0.81 | LMNA (0.50) | ALDH1A1MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL394740 | 0.79 | ALDH1A1 (0.56) | ALDH1A1MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL17596712 | 0.79 | ALDH1A1 (0.42) | ALDH1A1MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1119176 | 0.79 | CES2 (0.59) | ALDH1A1MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL10047298 | 0.78 | CES1 (0.52) | ALDH1A1MEN1KMT2AL3MBTL1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118770-A1 | N-Heterocyclic Phosphines | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118770-A1 | N-Heterocyclic Phosphines | NANP, PPIP5K2, PHPT1 | ALDH1A1 4621/4885MAPT 4371/4885MEN1 469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.